Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic
  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Supernus Pharmaceuticals ends low dose option in study

Supernus Pharmaceuticals Inc. (Nasdaq: SUPN) has eliminated a lower dose option of its Phase 3 clinical trial of SPN-810 to treat impulsive aggression in patients aged 6 to 12 years who have attention deficit hyperactivity disorder. The stock price plunged $11.60 to close at $38.05.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.